scholarly journals Proton and Carbon-ion Radiotherapy for High Grade Glioma: Early Results of the Shanghai Proton and Heavy Ion Center (SPHIC)

Author(s):  
Lin Kong ◽  
Jing Gao ◽  
Xianxin Qiu ◽  
Jiyi Hu ◽  
Xiyin Guan ◽  
...  
2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 2043-2043
Author(s):  
Patrick Salome ◽  
Francesco Sforazzini ◽  
Andreas Kudak ◽  
Laila König ◽  
Philipp Kickingereder ◽  
...  

2043 Background: Unique radiobiological and physical properties of carbon ion radiotherapy (CIRT) may be favorably utilized to improve outcome in recurrent High-Grade Glioma (rHGG). There are currently no standardized criteria for stratification of rHGG patients for re-irradiation (re-RT). This study evaluated the impact of morphological data (radiomics) and physical information (dosiomics) in stratifying rHGG patients for CIRT. Methods: Quantitative radiomics and dosiomics features were extracted from CIRT planning CTs with dose distribution (DD) and multiparametric MRIs (mpMRI, pre re-RT) of 141 patients (recurrent grade III: n=56 40%, grade IV: n=85 60%) treated with a median dose of 42 Gy (RBE) and a median fraction of 13. The MR sequences considered are T1 weighted pre-and post-contrast agent, fluid-attenuated inversion recovery (FLAIR) and apparent diffusion coefficient (ADC). Benefit of a re-RT risk score (RRRS), comprising the initial tumour grade, age and the Karnofsky Performance Score was shown to correlate with superior outcome in CIRT and conventional re-RT and was also studied here in parallel. Feature sets - a) RRRS, b) radiomics, c) dosiomics features - were evaluated both separately and combined. Multiple feature selection methods were used independently on the CT, DD and the MR sequences, followed by a stepwise Cox's Proportional Hazard model selection per modality or combination thereof. Multivariable models were ranked by 10-fold cross-validated concordance index (C-I). Results: Compared to the RRRS model (OS/PFS, C-I: 0.68/0.61), the multimodality model considering radiomics and dosiomics features (RD) allowed improved prognostic separation (OS/PFS, C-I: 0.77/0.70). The RD signature consisted of 12 and 10 textural features for the OS and PFS models. Combining the RD model with RRRS yielded the best performance (OS/PFS, C-I: 0.78/0.73). No significant correlation between the textural features and the prescribed dose, tumor grade and volume was found, with the Spearman's correlation coefficient ranging between -0.06 to 0.17. Conclusions: Integrating multimodal information outperforms unimodal prognostic separation of rHGG following CIRT, highlighting the importance to consider biological, physical and morphological data for patient stratification. Prospective validation studies of this multimodal stratifier is warranted.[Table: see text]


2019 ◽  
Vol 10 (15) ◽  
pp. 3315-3322 ◽  
Author(s):  
Shuang Wu ◽  
Ping Li ◽  
Xin Cai ◽  
Zhengshan Hong ◽  
Zhan Yu ◽  
...  

2010 ◽  
Vol 14 (1) ◽  
pp. 34-41 ◽  
Author(s):  
D. Maucort-Boulch ◽  
M.-H. Baron ◽  
P. Pommier ◽  
D.C. Weber ◽  
J.-E. Mizoe ◽  
...  

2021 ◽  
Author(s):  
Ping Li ◽  
Zhengshan Hong ◽  
Yongqiang Li ◽  
Xiaomao Guo ◽  
Shen Fu ◽  
...  

Abstract Purpose: The purpose of this study was to prospectively analyze the safety and feasibility of spot scanning carbon ion radiotherapy (CIRT) for patients with localized prostate cancer.Methods: 118 localized prostate cancer patients treated with spot scanning CIRT at Shanghai Proton and Heavy Ion Center (SPHIC) were enrolled in this dose escalated study. The dose was gradually increased from 59.2GyE to 65.6GyE in 16 fractions. The primary endpoint was the acute and late toxicities. Secondary endpoints were biochemical relapse free survival (bRFS), distant metastasis free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS).Results: The median follow-up time was 30.2 months (4.8-62.7 months). Acute grade 1 and 2 genitourinary (GU) toxicities were 15.3% and 18.6%, while acute grade 1 and 2 gastrointestinal (GI) toxicities were 2.5% and 0%, respectively. Late grade 1 and 2 GU toxicities were 4.2% and 1.7%, respectively. No late GI toxicity were observed. There were no cases of severe acute or late toxicity (≥grade 3). The significant association was not found between the factors and the acute GU toxicities except for CTV volume (p=0.031) on multivariate analysis. The 2-year bRFS, DMFS, PCSS, OS were 100%, 100%, 100% and 98.8%, respectively.Conclusion: The 2 years’ outcomes are encouraging, providing additional and useful information on the feasibility and safety of spot scanning CIRT for prostate cancer. Long term follow-up and prospective multi-institutional data are warranted to reinforce the role of CIRT in the management of localized prostate cancer.Trial registration: Clinicaltrial, NCT02739659. Registered 15 April 2016


Sign in / Sign up

Export Citation Format

Share Document